[go: up one dir, main page]

WO2001021195A1 - Composition et procede de traitement de brulures - Google Patents

Composition et procede de traitement de brulures Download PDF

Info

Publication number
WO2001021195A1
WO2001021195A1 PCT/US2000/026019 US0026019W WO0121195A1 WO 2001021195 A1 WO2001021195 A1 WO 2001021195A1 US 0026019 W US0026019 W US 0026019W WO 0121195 A1 WO0121195 A1 WO 0121195A1
Authority
WO
WIPO (PCT)
Prior art keywords
fibrin
template
composition
fibrinogen
silver sulfadiazine
Prior art date
Application number
PCT/US2000/026019
Other languages
English (en)
Inventor
William D. Spotnitz
Jeff Wang
George T. Rodeheaver
Original Assignee
Univ Virginia
Spotnitz William D
Jeff Wang
Rodeheaver George T
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia, Spotnitz William D, Jeff Wang, Rodeheaver George T filed Critical Univ Virginia
Priority to AU76041/00A priority Critical patent/AU7604100A/en
Publication of WO2001021195A1 publication Critical patent/WO2001021195A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
    • A61L2300/104—Silver, e.g. silver sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/62—Encapsulated active agents, e.g. emulsified droplets

Definitions

  • the present invention is directed to a biocompatible dressing for treating wounds, including burn wounds.
  • the dressing comprises preformed fibrin that functions as a non-adhesive covering of the burned surface as well as functioning as a delivery vehicle for pharmaceutical compounds that are entrapped within the fibrin clot.
  • Burn wounds present a significant medical challenge in that they represent one of the most painful conditions that an individual may experience. Not only is initial treatment difficult and often painful for the patient, but the risk of secondary bacterial infection is very high. In particular, infection secondary to burn wounds is estimated to cause 75% of all fatalities in treated burn patients. Increased susceptibility of burn wounds to infection remains until complete restoration of the dermis and overlying epidermis has occurred.
  • the standard treatment for such wounds includes the daily application of antimicrobial agents to prevent infection.
  • the most common topical antimicrobial treatment used to promote wound healing is silver sulfadiazine (SSD).
  • SSD provides antimicrobial activity against a number of pathogens such as Staphylococcus aureus, Escherichia coli, Klebsiella, Pseudomonas aeruginosa, Proteus, and Candida albicans, and is typically applied in the form a cream of polypropylene glycol containing SSD.
  • Topical administration of SSD in a cream provides for easy application and low toxicity, but the cream must be changed at least once if not the preferred twice per day. Removal of the cream, which is prerequisite for subsequent re-application, is a very painful experience for the patient in addition to being a rather labor-intensive and time-consuming procedure for medical personnel.
  • the present invention is directed to the use of fibrin sealant (FS) clots as a drug delivery system for antibiotics, growth factors, and chemotherapeutic agents.
  • FS fibrin sealant
  • the present invention is directed to a composition and method for treating wounds, and in particular burn wounds.
  • the composition comprises a plurality of non-adhesive preformed fibrin clots, wherein each clot contains a pharmaceutical agent, such as silver sulfadiazine, embedded within the fibrin clot matrix.
  • This composition functions as a slow release delivery system as well as providing an effective non-adhesive covering of the wound to enhance wound healing.
  • the fibrin/silver sulfadiazine formulations of the present invention can be topically applied at a greatly reduced frequency relative to the currently available cream-based silver sulfadiazine formulations. Decreasing the frequency of burn dressing changes results in less traumatic disturbances to the regenerating dermis and less pain to the patient.
  • an effective amount means an amount sufficient to produce a selected effect.
  • an effective amount of silver sulfadiazine is an amount sufficient to decrease the risk of infection.
  • a compound that "enhances tissue repair” includes any compound that decreases the overall time required to heal the damage relative to the repair of tissue in the absence of that compound.
  • Fibrin sealant is a well-known tissue adhesive that combines fibrinogen and thrombin to form fibrin. This agent has been used in a wide variety of surgical procedures as both a biological sealant and hemostat.
  • Conventional fibrin sealants consist of concentrated human fibrinogen, bovine aprotinin and factor XIII, as the first component and bovine thrombin and calcium chloride as the second component.
  • Aprotinin is a fibrinolytic inhibitor added to promote stability of fibrin sealants.
  • the plasma fibrinogen/Factor XIII component of fibrin sealant is typically prepared by freezing plasma at a temperature below -20°C overnight, slowly thawing the material at 0°C to 4°C, centrifuging, and transferring the cryoprecipitate to a syringe or spray container (Dresdale et al, Ann. Thorac. Surg. 40:385 1985; and U.S. Pat. No. 4,627,879).
  • Fibrin sealants can also be prepared using autologous fibrin, wherein the fibrinogen component of the fibrin sealant is extracted from the patient's own blood.
  • an autologous fibrin sealant is preferred because it eliminates the risk of transmission of blood-transmitted infections, e.g., hepatitis B, non A, non B hepatitis and acquired immune deficiency syndrome (AIDS), that could otherwise be present in the fibrinogen component extracted from pooled human plasma.
  • the fibrinogen component can be obtained commercially.
  • the thrombin component usually purified from bovine plasma, can also be obtained commercially.
  • the two solutions are delivered simultaneously or alternately to generate fibrin sealant at the desired site. Application is generally carried out with a double-barreled syringe, which permits simultaneous application of both components to the site where one wants to form the fibrin clot.
  • the present invention is directed to the use of fibrin as a non-adhesive wound dressing rather than as an adhesive sealant.
  • fibrin is prepared in accordance with the present invention using a standard two-component technique.
  • concentrated fibrinogen is prepared from human plasma obtained from a hospital blood bank. The prepared fibrinogen is then tested for hepatitis B surface antigen and core antibody, hepatitis C antibody, HIV I and II antibody, and HTLV I antibody.
  • fibrinogen is combined with 4 ml of commercially available bovine thrombin (1,000 NIH units/ml, Johnson & Johnson, Arlington, Tex.) to form fibrin.
  • bovine thrombin 1,000 NIH units/ml, Johnson & Johnson, Arlington, Tex.
  • the fibrinogen and thrombin are mixed together under conditions that allow polymerization, and the coagulated fibrin clot is used as a dressing for the wound.
  • fibrin compositions of the present invention are pre-formed and applied to the wound site as a non-adhesive cover for the wound.
  • the fibrin clot is formed in the presence of one or more pharmaceutical agents, thus entrapping the pharmaceutical agent within the fibrin clot matrix.
  • the pharmaceutical agent is released in a time-dependent manner by diffusion and the biodegradation of the fibrin matrix.
  • the fibrin compositions of the present invention provide a delivery system for antibiotics, growth factors, and chemotherapeutic agents.
  • the fibrin/silver sulfadiazine formulations of the present invention are used for treating bums.
  • This composition has been found to have surprising efficacy for treating bums due in part to the fact that the composition can be topically applied at a greatly reduced frequency relative to the currently available cream-based silver sulfadiazine formulations.
  • Topical administration of cream-based silver sulfadiazine formulations require frequent changes at least once if not the preferred twice per day. Removal of the cream, which is prerequisite for subsequent re-application, is a very painful experience for the patient in addition to being a rather labor-intensive and time-consuming procedure for medical personnel.
  • the novel compositions of the present invention by substantially decreasing the frequency of bum dressing changes and lack of adhesion to the wound, enhance the repair process and decrease pain to the patient.
  • the compositions can retain antibiotic effectiveness up to 96 hours after application.
  • the composition for treating bums comprises a plurality of fibrin clots in particulate form, wherein each clot contains a pharmaceutical formulation for treating bums.
  • the pharmaceutical formulation may comprise antibiotics, moisturizing agents, growth factors and other agents know to enhance the wound healing response.
  • the pharmaceutical formulation comprises silver sulfadiazine.
  • the fibrin clots are formed as discrete particles by mixing a solution of fibrinogen with a solution of thrombin and alliquoting equal portions onto a substrate that allows the removal of the formed clot in its entirety.
  • the silver sulfadiazine is dispersed in the fibrinogen solution rather than in the thrombin solution since mixing in the fibrinogen solution was found to give a better dispersal of the silver sulfadiazine.
  • Devices that are used for mixing the fibrinogen and thrombin solutions and for spraying such mixtures have been previously described and are known to those skilled in the art.
  • the fibrin clots are prepared using a base template, wherein the template is provided with a plurality of chambers having predefined dimensions, to produce individual clots having the optimal surface to volume ratio for a given application.
  • the shape of the clots will vary based on the size and type of wound to be treated.
  • the fibrin clot can be formed as a non- adhesive sheet having a surface area of about 1.0 cm 2 to about 40.0 cm 2 for contact with the wound. More preferably, the fibrin clot is formed to have a surface area of about 1.0 cm 2 to about 15 cm 2 and in one embodiment a plurality of fibrin clots are formed to have a surface area of about 1.0 cm 2 to about 5 cm 2 for contact with the wound. In accordance with one embodiment the fibrin clots have an average volume of about 0.1 cm 3 to about 40.0 cm 3 and more preferably from about 1.0 cm 3 to about 15.0 cm 3 . In one embodiment a dressing is prepared for treating a bum wherein the dressing comprises a plurality of fibrin clots having a disk-like or spherical shape and an average volume of approximately 1.0 cm 3 to about 5.0 cm 3 .
  • compositions of the present invention are prepared by mixing the preselected pharmaceutical composition with a solution of thrombin and fibrinogen, alliquoting discrete portions of the solution onto a substrate prior to coagulation, and coagulating the solution on the substrate to form fibrin clots.
  • the pharmaceutical agent is dispersed in either the thrombin or the fibrinogen solution shortly before the two solutions are mixed to form the fibrin clot.
  • the pharmaceutical composition comprises silver sulfadiazine
  • the step of preparing the fibrin clot comprises the steps of dispersing the silver sulfadiazine in a solution of fibrinogen to form a suspension, and then mixing the suspension with thrombin.
  • the base template further comprises a non-porous deformable surface layer covering the surface of the solid base.
  • the deformable surface layer may be a latex covering that has a native shape that approximates the shape of the template (i.e. the deformable surface is formed to have depressions that match the wells of the template).
  • the fibrinogen/thrombin mixture is applied to each well onto the non- porous deformable surface layer and the method of releasing the fibrin clots comprises the step of altering the conformation of the deformable surface layer (i.e. by stretching the surface layer).
  • the fibrinogen/thrombin mixture is applied to a substrate wherein the substrate comprises a deformable non-porous layer covering a solid block template.
  • the template is formed to have a plurality of depressions or wells, each having the same dimensions.
  • each well is provided with a port, preferably at the bottom of the well wherein the port is in communication with a vacuum source.
  • the deformable non- porous layer (preferably a latex or rubberized material) has a relatively planar native shape and overlays the top surface of the solid block template, covering each of the wells.
  • the non-porous layer is fixed to the solid block template along at least one of the top surface edges or sides of the solid block template.
  • the deformable non-porous layer Upon application of a vacuum, the deformable non-porous layer is drawn into the well and conforms to the shape of the template well.
  • the fibrinogen/thrombin mixture can then be portioned out to each well and allowed to coagulate. After coagulation is complete the applied vacuum is released to alter the shape of the deformable non- porous layer and ease the removal of the formed clots.
  • the fibrin clots can be formed as part of a semi-occlusive dressing using a similar procedure.
  • the semi-occlusive dressing is applied to the deformable surface layer and the vacuum is applied to form fit the dressing into the wells of the template.
  • the fibrinogen/thrombin mixture in combination with SSD is then added to the wells and a top plate is placed over the wells and the vacuum is applied until the fibrin clots are fully coagulated.
  • the vacuum is then removed and the dressing with the preformed clots is applied to the wound, or stored for latter use.
  • the fibrin compositions of the present invention can be used to enhance the repair of bum damaged tissues and reduce the discomfort associated with such tissue damage and the subsequent therapeutic treatments.
  • the fibrin clots containing silver sulfadiazine have been found to have a surprising efficacy in stimulating the repair of bums.
  • the fibrin clot provides a non-adhesive cover that can be easily removed to allow a fresh dressing to be applied and in addition the fibrin itself stimulates the healing process.
  • the silver sulfadiazine component provides an effective antibiotic therapy to keep the wound clean. Therefore in accordance with one embodiment a method is provided for enhancing the repair of wounds, and in particular bums.
  • the method comprises the steps of contacting the damaged tissue with a composition comprising a plurality of fibrin clots, wherein each clot contains a pharmaceutical composition embedded within the fibrin clot matrix.
  • the pharmaceutical composition comprises silver sulfadiazine.
  • a kit for treating bums, wherein the kit comprises a solution of fibrinogen, a solution of thrombin and silver sulfadiazine.
  • the fibrinogen, thrombin and silver sulfadiazine are combined, mixed and allowed to coagulate to form a fibrin clot, wherein the silver sulfadiazine is entrapped within the fibrin matrix.
  • the fibrinogen/thrombin/silver sulfadiazine mixture is alliquoted onto a semipermiable membrane to form discrete fibrin clots that contain the pharmaceutical composition entrapped within the fibrin clot.
  • the fibrin clots in particulate form are then applied to the would site as a dressing.
  • the fibrin/silver sulfadiazine formulations of the present invention can be topically applied at a greatly reduced frequency relative to the currently available cream-based silver sulfadiazine formulations. Decreasing the frequency of bum dressing changes results in less traumatic disturbances to the regenerating dermis and less pain to the patient.
  • the fibrin-based compositions of the present invention enhance the anti-bacterial effectiveness of silver sulfadiazine (see Table 1). Therefore, fibrin in combination with silver sulfadiazine provides a superior alternative to current methods of bum treatment.
  • FS+SSD saline controls
  • SV Silvadene
  • the wound area was covered with a 2 in x 3 in semi-occlusive dressing (Uniflex, Smith and Nephew, Largo, FL) and allowed to incubate for 24 hours. Treatments were then applied as specified for 6 days. On Day 7 the wounds were cleaned and no agent applied. On Day 8, an 8 mm punch biopsy was taken from each wound and the number of bacteria present quantified (log/cm 2 ).
  • FS+SSD significantly decreases bacterial counts when compared to both saline controls and SV.
  • the FS+SSD carrier provides improved anti-microbial protection with less frequent dressing changes. Decreasing the frequency of bum dressing changes should result in less traumatic disturbances to the regenerating dermis and less pain to the patient. Therefore, FS+SSD is a superior alternative to current methods of bum treatment.
  • the fibrin sealant employed in this study was obtained from a commercial product (Tisseel, Baxter, Deerfield, IL).
  • the concentrations of the two components in the Tisseel kit, fibrinogen and thrombin, were altered for the purpose of reproducing and expanding previous work done in this area (see Table 2).
  • the fibrinogen was reconstituted according to manufacturer instructions, using the specified amount of aprotinin.
  • An equal quantity of neutral sterile saline was then added by syringe to achieve a 1 :2 dilution, resulting in a concentration of approximately 50 mgs/ml.
  • Thrombin was also reconstituted according to standard procedure, requiring the given amount of CaCl 2 in the kit. This mixture was then diluted with the necessary quantity of filter-sterilized 40mM CaCl 2 in 0.9% NaCl to achieve the desired concentration of 10 units/ml. This represents a 1:50 dilution of the commercial product.
  • SSD powder (Lek, Ljubljana, Slovenia) was added to an empty syringe into which the aprotinin was drawn during the reconstitution of fibrinogen.
  • the SSD powder was added in a 2% (w/w) ratio with fibrinogen.
  • the density of fibrinogen was assumed to be 1 g/cm 3 .
  • Treatment dressings, or clots, were created on portions of sterile powder-free latex surgical gloves through the use of a vacuum driven template.
  • the template contained a small well (1 1/4" x 1 1/4" x 1/16") over which a piece of latex could be placed.
  • the template was connected via rubber tubing to laboratory vacuum. When vacuum was applied, the latex was pulled into the template well and tightly adhered to its dimensions, which were designed to be the desired size of the treatment clot.
  • the experimental population consisted of 105 female Sprague-Dawley rats (240-260 g). On the first day of treatment (day -1), the animals were anesthetized using a combination of ketamine and xylizine (50 mg/kg, 5 mg/kg). The dorsal hair of each animal was then removed by clipping and depilatory cream (Neet, Premier, Englewood, NJ). The surgical site was prepared with scrub solution, betadine, isopropyl alcohol, and thiosulfate. Using a Brown dermatome, each animal received a 1" x 1" split thickness wound (0.015") on the dorsum directly inferior to the scapulae.
  • Hemostasis was achieved through pressure applied with sterile gauze. The wounds were analyzed and specific details recorded. A 1 ml syringe was then used to topically inoculate the wound site of each animal with 0.05 ml of saline solution containing 10 6 Pseudomonas aeruginosa (ATTC #10145). The inoculum was stored on ice during the procedure to prevent excessive changes in bacterial population. After wounding, tincture of benzoin (Humco, Texarkana, TX) was applied around the borders of the wound which was then covered with a 2" x 3" transparent semi-occlusive dressing (Uniflex, Smith and Nephew, Largo, FL).
  • benzoin Haco, Texarkana, TX
  • the biopsy sample was placed in 5 ml of sterile saline and weighed. The sample was then ground in the saline to form a homogenate solution.
  • a four step 1 10 serial dilution was performed and 0.1 ml of each dilution was plated onto a t-soy agar plate and allowed to incubate at 36 C for 20 - 24 hours. After this time period, the Pseudomonas aeruginosa and contaminant populations were quantified (count/biopsy). The log/cm 2 and log/g were then calculated. The mean and standard deviation of each of these numbers for each sample was calculated.
  • the bacterial counts were generally greater within the saline control and the fibrin sealant alone treatments relative to the bacterial counts observed in the remaining four treatment groups. Bacterial counts were comparable between the saline control and the fibrin sealant alone treatments, and the bacterial counts were also comparable within the other four remaining treatment groups. However, the bacterial counts of the Fibrin Sealant + SSD treatments applied every 24 or 48 hours were lower than the bacterial counts obtained for treatment with SSD cream. Accordingly, the fibrin/SSD compositions of the present application provide at least an equivalent antibiotic efficacy as the SSD cream alone, without the frequent changes that are required for SSD cream application. Even the fibrin/SSD composition applied only at 96 hour intervals gave an equivalent bacterial count to a daily application of the SSD cream.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Materials Engineering (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition et un procédé de traitement de brûlures. Le procédé consiste à utiliser un caillot de fibrine non-adhérent comme vecteur d'administration et stimulateur de réparation de tissus.
PCT/US2000/026019 1999-09-24 2000-09-22 Composition et procede de traitement de brulures WO2001021195A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU76041/00A AU7604100A (en) 1999-09-24 2000-09-22 Composition and method for treating burns

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15597399P 1999-09-24 1999-09-24
US60/155,973 1999-09-24

Publications (1)

Publication Number Publication Date
WO2001021195A1 true WO2001021195A1 (fr) 2001-03-29

Family

ID=22557534

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/026019 WO2001021195A1 (fr) 1999-09-24 2000-09-22 Composition et procede de traitement de brulures

Country Status (2)

Country Link
AU (1) AU7604100A (fr)
WO (1) WO2001021195A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008103673A1 (fr) 2007-02-19 2008-08-28 Plurogen Therapeutics, Inc. Compositions pour traiter des biofilms, et procédés pour leur utilisation
WO2010086848A2 (fr) 2009-01-27 2010-08-05 Alon Kushnir Pansements, procédés et appareils de fabrication de ceux-ci, leur stockage et leur utilisation
US8980243B2 (en) 2009-05-19 2015-03-17 Neal Koller Surface active agent compositions and methods for enhancing oxygenation, reducing bacteria and improving wound healing at a site of treatment
US10456416B2 (en) 2015-01-20 2019-10-29 Plurogen Therapeutics, Llc Compositions and methods of treating microbes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900361A (en) * 1994-12-09 1999-05-04 Board Of Regents, The University Of Texas System System and method for rapid positioning of cells on a substratum

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900361A (en) * 1994-12-09 1999-05-04 Board Of Regents, The University Of Texas System System and method for rapid positioning of cells on a substratum

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008103673A1 (fr) 2007-02-19 2008-08-28 Plurogen Therapeutics, Inc. Compositions pour traiter des biofilms, et procédés pour leur utilisation
EP2120561A4 (fr) * 2007-02-19 2012-11-21 Plurogen Therapeutics Inc Compositions pour traiter des biofilms, et procédés pour leur utilisation
US8871248B2 (en) 2007-02-19 2014-10-28 Plurogen Therapeutics, Inc. Compositions for treating biofilms and methods for using same
US9283278B2 (en) 2007-02-19 2016-03-15 Plurogen Therapeutics, Inc. Compositions for treating biofilms and methods for using same
US9603966B2 (en) 2007-02-19 2017-03-28 Plurogen Therapeutics, Inc. Compositions for treating biofilms and methods for using same
EP3170396A1 (fr) * 2007-02-19 2017-05-24 Plurogen Therapeutics, Inc. Compositions de traitement des biofilms et procédés d'utilisation de celles-ci
US9884136B2 (en) 2007-02-19 2018-02-06 Plurogen Therapeutics, Inc. Compositions for treating biofilms and methods for using same
WO2010086848A2 (fr) 2009-01-27 2010-08-05 Alon Kushnir Pansements, procédés et appareils de fabrication de ceux-ci, leur stockage et leur utilisation
US9180142B2 (en) 2009-01-27 2015-11-10 Reddress Ltd. Wound dressings, methods and apparatus for making same and storage and use thereof
US10111979B2 (en) 2009-01-27 2018-10-30 Reddress Ltd. Wound dressings, methods and apparatus for making same and storage and use thereof
US8980243B2 (en) 2009-05-19 2015-03-17 Neal Koller Surface active agent compositions and methods for enhancing oxygenation, reducing bacteria and improving wound healing at a site of treatment
US10456416B2 (en) 2015-01-20 2019-10-29 Plurogen Therapeutics, Llc Compositions and methods of treating microbes

Also Published As

Publication number Publication date
AU7604100A (en) 2001-04-24

Similar Documents

Publication Publication Date Title
US6054122A (en) Supplemented and unsupplemented tissue sealants, methods of their production and use
USRE39192E1 (en) Supplemented and unsupplemented tissue sealants, methods of their production and use
US3777016A (en) Composition and method for the treat-ment of damaged skin
US7208179B1 (en) Methods for treating disease and forming a supplemented fibrin matrix
US6559119B1 (en) Method of preparing a tissue sealant-treated biomedical material
US6197325B1 (en) Supplemented and unsupplemented tissue sealants, methods of their production and use
WO1996040174A1 (fr) Produits d'obturation tissulaires completes et non completes, leurs procedes de production et d'utilisation
JPH09504719A (ja) 止血パッチ
US5957877A (en) Methods for draping surgical sites using peripheral cyanoacrylate drapes
EP2292257A2 (fr) Compositions et methodes de cicatrisation pour lesions dermatologiques
Augustine et al. Role of wound dressings in the management of chronic and acute diabetic wounds
Williams Algosteril calcium alginate dressing for moderate/high exudate
WO2001021195A1 (fr) Composition et procede de traitement de brulures
EP3710044B1 (fr) Traitement de plaie contenant du collagène et un agent de réduction de gélatine, et méthode d'aide à la cicatrisation de plaie
Witkowski et al. Debridement of cutaneous ulcers: medical and surgical aspects
Wynn-Williams et al. The effects of povidone-iodine in the treatment of burns and traumatic losses of skin
Graham Rabbit wound management
Hanson et al. Degloving injuries of the distal aspect of the limb
RU2308960C1 (ru) Ранозаживляющая губка
Foutsizoglou A practical guide to the most commonly used dressings in wound care
US20060009373A1 (en) Method for treating diabetic wounds
RU56815U1 (ru) Перевязочный материал
Iman MANAGEMENT OF EXUBERANT GRANULATIING WOUNDS IN EQUINE DISTAL LIMB: NEW THERAPEUTIC ATTEMPETS
Cruz Wound management and infections of synovial structures
RU2319507C1 (ru) Способ лечения трофической язвы и средство для его осуществления

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP